DPA-714
DPA-714 or ''N'',''N''-diethyl-2-[4-(2-fluoroethoxy)phenyl]-5,7-dimethylpyrazolo[1,5-''a'']pyrimidine-3-acetamide is a selective ligand for the translocator protein (TSPO) currently under evaluation for several clinical applications. For this reason, a practical, multigram synthetic route for its preparation has been described. The binding affinity of DPA-714 for TSPO is reported as ''K''i = 7.0 ± 0.4 nM. [18F]DPA-714 is currently under investigation as a potential radiopharmaceutical for imaging TSPO in living systems using positron emission tomography (PET). DPA-714, along with other members of the DPA class of TSPO ligands, has been shown to decrease microglial activation and increase neuronal survival in a quinolinic acid rat model of excitotoxic neurodegeneration, suggesting potential neuroprotective effects. See also * DPA-713 References

{{Translocator protein modulators Pyrazolopyrimidines TSPO ligands Fluoroethyl ethers ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]  

DPA-713
DPA-713 or ''N'',''N''-diethyl-2-(4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-''a'']pyrimidine-3-acetamide is a selective ligand for the translocator protein (TSPO). The binding affinity of DPA-713 for TSPO is reported as ''K''i = 4.7 ± 0.2 nM. DPA-713 has been radiolabelled with carbon-11 as a potential radiotracer for imaging the TSPO using positron emission tomography (PET). Radiation dosimetry and biodistribution of [11C]DPA-713 have been assessed in healthy volunteers, indicating that [11C]DPA-713 is a suitable radiotracer for imaging the TSPO in humans. See also * DPA-714 References

{{Translocator protein modulators Pyrazolopyrimidines TSPO ligands ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]